Sort   by:  
 Page size 
ProteomicsImmune response biomarker profiling of serum from prostate cancer patients treated with anti-CTLA-4 immunotherapy.
Anti-CTLA-4 induced antibody responses to antigens in prostate cancer patients. Pre-treatment and post-treatment sera from 5 clinical responders and 6 clinical non-responders were used to hybridize protein arrays.
ORGANISM(S): Homo sapiens 
2012-11-05 | E-GEOD-39688 | biostudies-arrayexpress
UnknownI kappa B kinase alpha (IKKα) activity is required for functional maturation of dendritic cells and acquired immunity to infection.
Not available
S-EPMC3604721 | biostudies-literature
UnknownSuppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Not available
S-EPMC6499401 | biostudies-literature
UnknownComputationally restoring the potency of a clinical antibody against Omicron.
Not available
S-EPMC11111397 | biostudies-literature
UnknownDo worsening lung ultrasound scans identify severe COVID-19 trajectories?
Not available
S-EPMC9720255 | biostudies-literature
Genomicsena-DATASET-GNE-27-07-2018-23:28:18:139-1120 - samples
Tumor DNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. Normal DNA was extracted from matched PBMCs. Whole exome sequencing was performed. This is a subset of patients for which RNA sequencing is also pro...
EGAD00001004218 | EGA
Genomicsena-DATASET-GNE-22-02-2018-22:43:32:906-1098 - samples
RNA was extracted from formalin-fixed and paraffin embedded tumors of a large cohort of bladder cancer patients before treatment with anti-PD-L1. RNA was sequenced using a capture based approach (exome capture, RNA access).
EGAD00001003977 | EGA
GenomicsTGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
We examined tumours from a large cohort of patients with metastatic urothelial bladder cancer (mUC) treated with an anti–PD-L1 agent (atezolizumab) and identified major determinants of clinical response and immune escape. Whole transcriptome profiles were generated for 368 patients using TruSeq RNA ...
EGAS00001002556 | EGA
GenomicsData access committee handling data access requests for biomarker data from the clinical trial IMvigor210.
Data Access Committee EGAC00001000945
EGAC00001000945 | EGA
UnknownIntracerebroventricular enzyme replacement therapy with β-galactosidase reverses brain pathologies due to GM1 gangliosidosis in mice.
Not available
S-EPMC7521651 | biostudies-literature
Sort   by:  
 Page size